ANDA 203424, held by Pharmobedient. Carbidopa; Entacapone; Levodopa.
As of Nov 16, 2026, ANDA 203424 (Carbidopa, Levodopa And Entacapone), held by Pharmobedient, was first approved by FDA on Aug 13, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 13, 2020 | Original application | Approved | None posted |
| Carbidopa, Levodopa And Entacapone12.5MG;200MG;50MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Discontinued |
| Carbidopa, Levodopa And Entacapone18.75MG;200MG;75MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Discontinued |
| Carbidopa, Levodopa And Entacapone25MG;200MG;100MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Discontinued |
| Carbidopa, Levodopa And Entacapone31.25MG;200MG;125MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Discontinued |
| Carbidopa, Levodopa And Entacapone37.5MG;200MG;150MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Discontinued |
| Carbidopa, Levodopa And Entacapone50MG;200MG;200MG · tablet;oral | Carbidopa; Entacapone; Levodopa | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters